Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: EC:5.4.2.8 (phosphomannomutase)
 238 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

We have cloned the human homologue of SEC53 or yeast phosphomannomutase (HGMW-approved symbol PMM1) from a liver cDNA library. This cDNA encodes a protein of 262 amino acids with a predicted molecular mass of 29 kDa and 54% identity with yeast phosphomannomutase. Expression of the human cDNA in Escherichia coli yielded an active phosphomannomutase, which was purified to homogeneity. Northern blot analysis of human tissues showed strong expression in liver, heart, brain, and pancreas and a lower expression in skeletal muscle. The gene was assigned to chromosome 22q13.1 by the use of hybrid cell lines and by fluorescence in situ hybridization. Most patients presenting with carbohydrate-deficient glycoprotein syndrome type 1 (CDG1 or Jaeken disease) have a greatly reduced phosphomannomutase activity; the gene encoding this enzyme is a likely candidate for CDG1. Since the CDG1 locus maps else where in the genome (16p13), mutations in the phosphomannomutase gene encoded by chromosome 22 are not a major cause of CDG1.
 ...
PMID:PMM (PMM1), the human homologue of SEC53 or yeast phosphomannomutase, is localized on chromosome 22q13. 907 Sep 17

Carbohydrate-deficient glycoprotein syndrome type 1 (CDG1 or Jaeken syndrome) is the prototype of a class of genetic multisystem disorders characterized by defective glycosylation of glycoconjugates. It is mostly a severe disorder which presents neonatally. There is a severe encephalopathy with axial hypotonia, abnormal eye movements and pronounced psychomotor retardation, as well as a peripheral neuropathy, cerebellar hypoplasia and retinitis pigmentosa. The patients show a peculiar distribution of subcutaneous fat, nipple retraction and hypogonadism. There is a 20% lethality in the first years of life due to severe infections, liver insufficiency or cardiomyopathy. CDG1 shows an autosomal recessive mode of inheritance and has been mapped to chromosome 16p. Most patients show a deficiency of phosphomannomutase (PMM)8, an enzyme necessary for the synthesis of GDP-mannose. We have cloned the PMM1 gene, which is on chromosome 22q13 (ref.9). We now report the identification of a second human PMM gene, PMM2, which is located on 16p13 and which encodes a protein with 66% identity to PMM1. We found eleven different missense mutations in PMM2 in 16 CDG1 patients from different geographical origins and with a documented phosphomannomutase deficiency. Our results give conclusive support to the biochemical finding that the phosphomannomutase deficiency is the basis for CDG1.
 ...
PMID:Mutations in PMM2, a phosphomannomutase gene on chromosome 16p13, in carbohydrate-deficient glycoprotein type I syndrome (Jaeken syndrome). 914 Apr 1

The carbohydrate-deficient glycoprotein syndromes are multisystemic inherited diseases with severe nervous system involvement. There is indirect evidence for deficiency of phosphomannomutase in type I and direct evidence for a deficiency of N-acetylglucosaminyltransferase II in type II. The disease is characterized by carbohydrate deficiencies of a number glycoproteins, including serum sialotransferrins.
 ...
PMID:[Metabolic disorders in patients with primary carbohydrate deficient glycoprotein syndrome]. 923 66

Patients with carbohydrate-deficient glycoprotein syndrome (CDGS) Type 1 underglycosylate many glycoproteins by failing to add entire N-linked carbohydrate chains to them. The primary defect in these patients has been reported as a > 90% deficiency in phosphomannomutase activity (PMM), the enzyme that converts mannose-6-phosphate to mannose-1-phosphate. This lesion reduces both the amount and the size of the lipid-linked oligosaccharide precursor. We have now analyzed the activity of PMM and the level of glycosylation in cultured fibroblasts as well as the level of blood mannose in seven CDGS Type 1 patients and their parents. All of these patients were approximately 95% deficient in PMM activity and their parents had an average of 51% of control PMM activity. Furthermore, parental fibroblasts showed reduced glycosylation and a higher proportion of truncated N-linked chains compared to those made by control fibroblasts. Addition of 0.25 mM mannose to the culture medium corrected both the underglycosylation and size of the oligosaccharide chains in CDGS Type 1 patients and their parents. Finally, serum from CDGS patients had considerably reduced mannose levels (5-40 microM) compared to normal controls (40-80 microM) and some parents were below normal (16-103 microM). These results suggest that the reduced blood mannose level is a consequence of the PMM deficiency. This is the first inherited disorder in human metabolism that shows a decrease in available mannose. Increasing blood mannose levels might correct some protein underglycosylation in these patients.
 ...
PMID:Abnormal metabolism of mannose in families with carbohydrate-deficient glycoprotein syndrome type 1. 925 81

Carbohydrate-deficient glycoprotein syndrome consists of a group of disorders with multisystemic involvement and prominent neurologic symptoms. The full clinical spectrum continues to evolve, with four types currently recognized; type I is by far the most common. The clinical presentation of CDGS appears more severe in infants than in adults. Diagnosis is based on the clinical findings of characteristic fat distribution, neurologic impairment, and developmental delay, combined with the biochemical finding of cathodally migrating serum glycoproteins, transferrin in particular, on isoelectric focusing. Scientific evidence supports the hypothesis that abnormal synthesis of N-linked oligosaccharides is the basic metabolic defect in CDGS. The complex, multistep nature of the N-linked oligosaccharide pathway and the clinical heterogeneity of CDGS suggest that several different defects in the pathway can result in this disorder. Two specific enzyme defects have been reported: phosphomannomutase deficiency in some type I patients and N-acetylglucosamine transferase II deficiency in type II patients. Investigations continue into other metabolic bases of CDGS. The discovery of some of the enzyme defects paves the way for cloning, mutational analysis, and eventually prenatal diagnosis in appropriate families. No known treatment exists for CDGS; pallintive care and support is the most that can be offered. Family support systems are blossoming both in the United States and abroad, giving families the ability to communicate with each other and with workers in the field. As more cases are diagnosed and scientific research continues, advances in clinical definition, supportive care, nutrition, and prenatal diagnosis of CDGS are inevitable.
 ...
PMID:Carbohydrate-deficient glycoprotein syndrome. 926 69

Carbohydrate-deficient glycoprotein syndrome type I (CDGI) is most often due to phosphomannomutase deficiency; paradoxically, the human phosphomannomutase gene PMM1 is located on chromosome 22, whereas the CDGI locus is on chromosome 16. We show that phosphomannomutases present in rat or human liver share with homogeneous recombinant PMM1 several kinetic properties and the ability to form an alkali- and NH2OH-sensitive phosphoenzyme with a subunit mass of approximately 30,000 Mr. However, they have a higher affinity for the activator mannose-1,6-bisphosphate than PMM1 and are not recognized by anti-PMM1 antibodies, indicating that they represent a related but different isozyme. Phosphomannomutases belong to a novel mutase family in which the active residue is a phosphoaspartyl or a phosphoglutamyl.
 ...
PMID:Comparison of PMM1 with the phosphomannomutases expressed in rat liver and in human cells. 927 Dec 15

The effects on isoelectrofocusing patterns of serum glycoproteins were studied in a patient with CDG syndrome type I and phosphomannomutase deficiency during 3 weeks of continuous intravenous mannose infusion. Doses of 5.7 g/kg/day led to stable serum mannose levels up to 2.0 mmol/l and were well tolerated without signs of liver or renal toxicity. While most of the pathological glycoprotein patterns, including alpha1-antitrypsin, typical for CDG syndrome type I remained unchanged, mannose infusion led to a unique change of the isoelectrofocusing pattern of serum sialotransferrins with appearance of two extra bands after 3 weeks of treatment.
 ...
PMID:Continuous mannose infusion in carbohydrate-deficient glycoprotein syndrome type I. 935 Sep 1

Phosphomannomutase (PMM) catalyzes the conversion of mannose-6-phosphate to mannose-1-phosphate, which is a substrate for the synthesis of GDP-mannose. This nucleotide sugar is then used in the synthesis of dolichol-phosphate-mannose, which is essential for N-linked glycosylation and thus the secretion of several glycoproteins as well as for the synthesis of glycosyl-phosphatidyl-inositol (GPI) anchored proteins. In the yeast Saccharomyces cerevisiae, SEC53, a gene required for viability, encodes PMM. Given the importance of PMM in glycoprotein synthesis, it is surprising that very little is known about the enzyme in higher eukaryotes. Recently, an autosomal recessive human disease, Carbohydrate-deficient glycoprotein syndrome type I (CDGS-I) has been correlated with severely reduced PMM activity. Here we report the isolation of a cDNA encoding human PMM, a protein of 29 kDa that is 55% identical and 66% similar to yeast Sec53p. Northern blot analysis shows a single 1.4 kb transcript that is ubiquitously expressed, although levels vary markedly among tissues. Expression of the human cDNA in a temperature-sensitive mutant sec53 yeast strain confers growth at the restrictive temperature, strongly suggesting that this gene encodes a functional PMM. Finally, when expressed in BHK cells, PMM is localized exclusively to the cytosol corresponding to its localization in yeast.
 ...
PMID:Cloning and characterization of human phosphomannomutase, a mammalian homologue of yeast SEC53. 937 85

The mRNA levels of algA, algC and algD genes increased, coordinately, in cells of the highly mucoid Pseudomonas aeruginosa 8821M grown under increasing dissolved oxygen tensions (DOT) of up to 70% of air saturation. These genes encode the bifunctional protein with phosphomannose isomerase (PMI) and GDP-mannose pyrophosphorylase (GMP) activities (algA), the phosphomannomutase (PMM) (algC) and the GDP-mannose dehydrogenase (GMD) (algD). These four enzyme activities are necessary for the synthesis of GDP-mannuronic acid, which is the activated sugar precursor for alginate polymerization. For growth-limiting DOT--lower than 10% of air saturation--the increase in mRNA levels of algA, algC and algD with oxygen concentration was accompanied by a strong increase in the activity of the encoded enzymes and the consequent increase in alginate synthesis. However, and despite the upregulation of alginate gene transcription by DOT above 10% of air saturation, the activities of the encoded enzymes either maintained (GMP and GMD) or decreased (PMI and PMM) their levels at high oxygen tensions, leading to a slight decrease in alginate synthesis. This has previously been attributed to the oxidative inactivation of alginate enzymes, particularly of PMM and PMI activities.
 ...
PMID:Oxygen-dependent upregulation of transcription of alginate genes algA, algC and algD in Pseudomonas aeruginosa. 940 3

The search for the carbohydrate-deficient glycoprotein syndrome type I (CDG1) gene has revealed the existence of a family of phosphomannomutase (PMM) genes in humans. Two expressed PMM genes, PMM1 and PMM2 , are located on chromosome bands 22q13 and 16p13, respectively, and a processed pseudogene PMM2 psi is located on chromosome 18p. Mutations in PMM2 are the cause of CDG type IA whereas no disorder has been associated with defects in PMM1 as yet. Here, we describe the genomic organization of these paralogous genes. There is a 65% identity of the coding sequence, and all intron/exon boundaries have been conserved. The processed pseudogene is more closely related to PMM2 . Remarkably, several base substitutions in PMM2 that are associated with disease are also present at the corresponding positions in the pseudogene. Thus, mutations that occur at a slow rate in the active gene in the population have also accumulated in the pseudogene.
 ...
PMID:Comparative analysis of the phosphomannomutase genes PMM1, PMM2 and PMM2psi: the sequence variation in the processed pseudogene is a reflection of the mutations found in the functional gene. 942 21


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>